Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2017 09:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017

NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that Peter G. Traber, M.D.,...
November 07, 2017 08:15 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update

All 52 weeks of infusions and 100% of the doses have been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial Top Line Results of NASH-CX Phase 2b Clinical Trial Expected to be...
October 20, 2017 08:30 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis

NORCROSS, Ga., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Raj...
September 12, 2017 08:30 ET | Source: Galectin Therapeutics

Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02

NORCROSS, Ga., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has...
August 18, 2017 08:30 ET | Source: Galectin Therapeutics

Clarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update

NORCROSS, Ga., Aug. 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, is issuing this press release to...
August 14, 2017 08:15 ET | Source: Galectin Therapeutics

Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update

NORCROSS, Ga., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
July 07, 2017 12:00 ET | Source: Galectin Therapeutics

Galectin Therapeutics to Present at the Singular Research Summer Conference

NORCROSS, Ga., July 07, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin,...
June 13, 2017 08:30 ET | Source: Galectin Therapeutics

Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial

NORCROSS, Ga., June 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and...
May 15, 2017 08:30 ET | Source: Galectin Therapeutics

Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update

NORCROSS, Ga., May 15, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
May 03, 2017 08:30 ET | Source: Galectin Therapeutics

Galectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease

NORCROSS, Ga., May 03, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of the Liver...

Next Page keyboard_arrow_right